Fulcrum Therapeutics, Inc. (FULC)
Market Cap | 306.02M |
Revenue (ttm) | 2.62M |
Net Income (ttm) | -98.71M |
Shares Out | 61.82M |
EPS (ttm) | -1.65 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 825,377 |
Open | 5.04 |
Previous Close | 4.95 |
Day's Range | 4.45 - 5.12 |
52-Week Range | 2.25 - 15.00 |
Beta | 2.18 |
Analysts | Buy |
Price Target | 11.25 (+142.98%) |
Earnings Date | Nov 7, 2023 |
About FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia is ... [Read more]
Financial Performance
In 2022, FULC's revenue was $6.34 million, a decrease of -66.90% compared to the previous year's $19.16 million. Losses were -$109.87 million, 35.9% more than in 2021.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for FULC stock is "Buy." The 12-month stock price forecast is $11.25, which is an increase of 142.98% from the latest price.
News

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically d...

Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of...

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023
― Completed enrollment in the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD); expect to report topline data in the fourth quarter of 2024 ―

Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to impr...

Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically ...

FDA Lifts Clinical Hold on Fulcrum Therapeutics' FTX-6058 for Sickle Cell Disease
CAMBRIDGE, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically d...

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023
― Screening closed for the Phase 3 REACH pivotal trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) ―

Fulcrum Therapeutics Appoints Chief Financial Officer
CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically ...

Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology
CAMP4 Therapeutics grants exclusive rights to advance novel therapies for Diamond-Blackfan Anemia CAMP4 Therapeutics grants exclusive rights to advance novel therapies for Diamond-Blackfan Anemia

FULC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 27, 2023 in the Class Action Filed on Behalf of Fulcrum Therapeutics, Inc. Shareholders
NEW YORK , June 27, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) alleging that ...

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fulcrum Therapeutics, Inc. (FULC)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 27, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors...

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulc...

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Fulcrum Investors of a Lead Plaintiff Deadline of June 27, 2023
NEW YORK , June 26, 2023 /PRNewswire/ -- Attention Fulcrum Therapeutics, Inc. ("Fulcrum") (NASDAQ: FULC) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commence...

FULC DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important June 27 Deadline in Securities Class Action - FULC
NEW YORK , June 25, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fulcrum Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FULC
NEW YORK , June 23, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC), and certain ...

FULC Investors Have Opportunity to Lead Fulcrum Therapeutics, Inc. Securities Fraud Lawsuit
LOS ANGELES , June 23, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against...

FINAL DEADLINE MONDAY: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 23, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulc...

FULC SHAREHOLDER ALERT: Jakubowitz Law Reminds Fulcrum Shareholders of a Lead Plaintiff Deadline of June 27, 2023
NEW YORK , June 23, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC). To ...

FULC LAWSUIT ALERT: Levi & Korsinsky Notifies Fulcrum Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , June 22, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC) of a class action securities lawsuit. CLASS ...

Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD)
Project Mercury unites patients, industry, research and clinical communities in groundbreaking initiative Project Mercury unites patients, industry, research and clinical communities in groundbreaking...

JUNE DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulc...

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulc...

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important June 27 Deadline in Securities Class Action - FULC
NEW YORK , June 17, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and ...

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 15, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulc...

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 14, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulc...